A phase I clinical trial of darinapars in in patients with refractory solid tumors

Clinical Cancer Research

Volumn 15, Issue 14, 2009, Pages 4769-4776

  Tsimberidou, Apostolia Maria ^a   Camacho, Luis H ^a   Verstovsek, Srdan ^a   Ng, Chaan ^a   Hong, David S ^a   Uehara, Cynthia K ^a   Gutierrez, Catalina ^a   Daring, Shawn ^a   Stevens, Jan ^b   Komarnitsky, Philip B ^b   Schwartz, Brian ^b   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ziopharm Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; DARINAPARSIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AGITATION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BLOOD LEVEL; CHORDOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DELIRIUM; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HALF LIFE TIME; HALLUCINATION; HUMAN; INFECTION; KIDNEY CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NERVOUSNESS; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESSNESS; SIDE EFFECT; SOLID TUMOR; THORAX PAIN; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; VOMITING;

AREA UNDER CURVE; ARSENICALS; ATAXIA; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 68049109550     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2984     Document Type: Article

References (42)

1. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6 Suppl 2:3-10. (Pubitemid 32405843)
2. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and α interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5:130-134 (Pubitemid 38519262)
3. Hussein MA. Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003;10:370-374
4. List A, Beran M, DiPersio J, et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003;17:1499-1507 (Pubitemid 36986951)
5. Golemovic M, Orsolic N, Zingaro R, et al. S-dimethylarsino-glutathione (SGLU1), an organic arsenic derivative as effective but less toxic than inorganic arsenic trioxide, has different mode of action [abstract]. Blood 2003;252b.
6. Golemovic M, Kantarjian H, Orsolic N, et al. Development of an organic arsenic derivative as a therapy for leukemia [abstract]. Blood 2003;252b.
7. Mann KK, Diaz Z, Marcoux S, et al. A novel arsenical, darinaparsin, induces apoptosis in arsenic trioxide-resistant and MRP1/ABCC1-overexpressing cell lines [abstract 264]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2008.
8. Diaz Z, Mann KK, Marcoux S, et al. A novel arsenical has antitumor activity toward As(2)O(3)-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 2008.
9. Kumagai Y, Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu Rev Pharmacol Toxicol 2007;47:243-262 (Pubitemid 46272130)
10. Komarnitsky PB, Qu Z, Schwartz B, Wallner B. ZIO-101 (S-dimethylarsino- glutathione): An oral multi-targeted anti-cancer drug with anti-angiogenic activity [abstract 4000]. Los Angeles (CA): American Association for Cancer Research Annual Meeting; 2007.
11. Camacho LH, Verstovsek S, Gutierrez C, et al. A novel organic arsenic molecule: ZIO-101 (S-dimethylarsino-glutathione) molecular biology and preliminary results of a phase-1 study in solid malignancies [abstract C90]. Philadelphia (PA): Proceedings of the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference; 2005.
12. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. Oncologist 2001;6 Suppl 2:29-32.
13. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072-1078 (Pubitemid 351871736)
14. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR α protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998;90:124-133 (Pubitemid 28114413)
15. Sternsdorf T, Puccetti E, Jensen K, et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor a mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19:5170-5178 (Pubitemid 29289555)
16. Amadori S, Fenaux P, Ludwig H, O'Dwyer M, Sanz M. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 2005;21:403-411 (Pubitemid 40490680)
17. Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001;6 Suppl 2:1-2. (Pubitemid 32405842)
18. Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 2006;7:192-198
19. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005;23:2396-2410 (Pubitemid 46218734)
20. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133:881-885
21. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001;97:1514-1516 (Pubitemid 32183782)
22. Westervelt P, Brown RA, Adkins DR, et al. Sudden death amongpat ients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001;98:266-271
23. Soignet SL, Tong WP, Hirschfeld S, Warrell RP, Jr. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999;44:417-421
24. Fox E, Razzouk BI, Widemann BC, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 2008;111:566-573
25. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107:3469-3473
26. Tsimberidou AM, Kantarjian H, O'Brien S, et al. All-trans retinoic acid and arsenic trioxide combination therapy induces high rates of durable molecular remission in newly diagnosed acute promyelocytic leukemia. In: Proceedings of the American Society of Hematology; 2007. p. 543a.
27. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505 (Pubitemid 350232226)
28. Bae ON, Lim KM, Noh JY, et al. Arsenite-enhanced procoagulant activity through phosphatidylserine exposure in platelets. Chem Res Toxicol 2007;20:1760-1768
29. Shen MC, Tseng WP, Chen CS. Increased circulating platelet aggregates and coagulation factors in patients with Blackfoot disease. Taiwan Yi Xue Hui Za Zhi 1983;82:816-821
30. Lee MY, Bae ON, Chung SM, Kang KT, Lee JY, Chung JH. Enhancement of platelet aggregation and thrombus formation by arsenic in drinking water: a contributing factor to cardiovascular disease. Toxicol Appl Pharmacol 2002;179:83-88
31. Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost 1995;74:224-227
32. Schror K. Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischaemia. Eur Heart J 1990;11 Suppl B:27-34. (Pubitemid 20181247)
33. Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997;272:L795-806.
34. Frishman WH, Grewall P. Serotonin and the heart. Ann Med 2000;32:195-209.
35. Ford MD. Arsenic. In: Goldfrank L, Flomenbaum N, Lewin N, Howland MA, Hoffman R, Nelson L, editors. Goldfrank's toxicological emergencies. New York: Mcgraw-Hill; 2002. p.1183.
36. ATSDR. Toxicological profile for arsenic. Atlanta (GA): U.S. Department of Health & Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 2000.
37. Danan M, Dally S, Conso F. Arsenic-induced encephalopathy. Neurology 1984;34:1524.
38. Mathieu D, Mathieu-Nolf M, Germain-Alonso M, Neviere R, Furon D, Wattel F. Massive arsenic poisoning-effect of hemodialysis and dimercaprol on arsenic kinetics. Intensive Care Med 1992;18:47-50.
39. Guha Mazumder DN, De BK, Santra A, et al. Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water. J Toxicol Clin Toxicol 2001;39:665-674
40. Vahidnia A, van der Straaten RJ, Romijn F, van Pelt J, van der Voet GB, deWolff FA. Arsenic metabolites affect expression of the neurofilament and H genes: an in vitro study into the mechanism of arsenic neurotoxicity. Toxicol In Vitro 2007;21:1104-1112
41. Vahidnia A, van der Straaten RJ, Romijn F, van Pelt J, van derVoet GB, deWolff FA. Mechanism of arsenic-induced neurotoxicity may be explained through cleavage of p35 to p25 by calpain. Toxicol InVitro 2008;22:682-687
42. Vahidnia A, van der Voet GB, de Wolff FA. Arsenic neurotoxicity - a review. Hum Exp Toxicol 2007;26:823-832